The group's principal activity is to develop and distribute an anti-malarial drug called malarex (formerly known as aspidos). Malarex is produced in two forms, capsules and injectables. It has had successful tests in the treatment and prevention of malaria and is continuing with further ongoing tests to allow it to receive final approval for consumer usage. The group acquired the rights to another anti-material agent, strychnos mytroides. The group is also engaged in developing and marketing an interactive knowledge based application system combined with intelligent agents in order to sort, create and transact medical data.
